BeiGene, Ltd. Stock price

Equities

BGNE

US07725L1026

Biotechnology & Medical Research

Delayed Nasdaq 04:00:00 2023-11-30 pm EST Intraday chart for BeiGene, Ltd. 5-day change 1st Jan Change
186.94 USD +2.08% +2.27% -15.00%
Sales 2023 * 2,412 M Sales 2024 * 3,030 M Capitalization 19.06 B
Net income 2023 * -907 M Net income 2024 * -840 M EV / Sales 2023 *
6,65x
Net cash position 2023 * 3,027 M Net cash position 2024 * 1,748 M EV / Sales 2024 *
5,72x
P/E ratio 2023 *
-24,1x
P/E ratio 2024 *
-24,4x
Employees 10,000
Yield 2023 *
-
Yield 2024 *
-
Free-Float 98.73%
More Fundamentals * Assessed data
Dynamic Chart
BeiGene Acquires Global License for CDK2 Inhibitor From Ensem Therapeutics MT
BeiGene to buy global rights to Ensem's experimental cancer therapy RE
BeiGene agrees to acquire Ensem Therapeutics' cancer therapy RE
Sector Update: Health Care Stocks Advance Premarket Friday MT
BeiGene Secures European Commission's Approval for Brukinsa as Follicular Lymphoma Treatment MT
BeiGene, Ltd. Receives European Commission Approval for BRUKINSA®? (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma CI
BeiGene Returns to Q3 Profit As Revenue Surges MT
BeiGene, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (BGNE) BEIGENE Reports Q3 Revenue $781M MT
Adaptive Biotechnologies Partners With BeiGene on Minimal Residual Disease Testing of Potential Treatments for Lymphoid Malignancies MT
Adaptive Biotechnologies Corporation Announces New Translational Collaboration to Measure Minimal Residual Disease with Clonoseq(R) Assay Across Beigene's Lymphoid Malignancy Pipeline CI
Nomura Adjusts BeiGene Price Target to $268.36 From $253.14, Maintains Buy Rating MT
Hong Kong Stocks Fall Over Slump in China Exports; Pharmaceuticals Make Losses Over Drug Price Cuts MT
Financial Firms Lead Asian Equities Traded in the US as American Depositary Receipts Lower in Monday Trading MT
Biotech, Solar Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Monday Trading MT
More news
1 day+2.08%
1 week+2.27%
Current month+0.35%
1 month+9.67%
3 months-12.48%
6 months-21.09%
Current year-15.00%
More quotes
1 week
180.94
Extreme 180.94
189.15
1 month
178.78
Extreme 178.775
205.40
Current year
156.56
Extreme 156.56
280.62
1 year
156.56
Extreme 156.56
280.62
3 years
118.18
Extreme 118.18
426.56
5 years
108.00
Extreme 108.0001
426.56
10 years
22.51
Extreme 22.51
426.56
More quotes
Date Price Change Volume
23-11-30 186.94 +2.08% 186,819
23-11-29 183.13 -0.93% 187,468
23-11-28 184.84 +1.03% 104,101
23-11-27 182.96 -0.95% 145,570
23-11-24 184.72 +1.05% 183,480

Delayed Quote Nasdaq, November 30, 2023 at 04:00 pm EST

More quotes
BeiGene, Ltd. is a global biotechnology company. The Company is focused on developing and commercializing oncology medicines to improve treatment outcomes and expand access for patients worldwide. The Company has discovered and developed three approved medicines including, BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; tislelizumab, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of PARP1 and PARP2. It has obtained approvals to market BRUKINSA in the United States, China, the European Union, the United Kingdom, Canada and Australia. The Company has in licensed the rights to distribute 13 approved medicines for the China market. BRUKINSA is a second-generation small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) designed to maximize BTK occupancy and minimize off-target binding effects.
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
186.94USD
Average target price
285.19USD
Spread / Average Target
+52.56%
Consensus
1st Jan change Capi.
-15.00% 19 064 M $
+22.87% 90 447 M $
+14.18% 85 991 M $
+1.98% 34 975 M $
+16.97% 26 060 M $
-33.16% 23 593 M $
-26.52% 20 576 M $
-2.42% 11 156 M $
+21.83% 10 875 M $
-37.27% 7 521 M $
Bio Therapeutic Drugs
  1. Stock
  2. Equities
  3. Stock BeiGene, Ltd. - Nasdaq
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration
fermer